10-Q: Vivos Therapeutics Reports Increased Revenue and Strategic Shift in Q3 2024

Vivos Therapeutics saw a revenue increase in Q3 2024, driven by product sales and a strategic shift towards alliances with sleep centers.

Summary

• Vivos Therapeutics reported a revenue increase of 17% to $3.9 million for the third quarter of 2024, compared to $3.3 million in the same period of 2023.
• The revenue growth was primarily driven by a $0.5 million increase in product revenue, particularly in appliance sales, and a $0.1 million increase in service revenue.
• The company experienced a decrease in VIP enrollment revenue, but this was offset by a higher incidence of contract breakage, which accelerated revenue recognition.
• Gross profit increased to $2.3 million, with a gross margin of 60% in Q3 2024, compared to 53% in Q3 2023.
• Operating expenses decreased, with general and administrative expenses down by 2% and sales and marketing expenses down by 46%.
• The company reported a net loss of $2.6 million for the quarter, an improvement from the $2.1 million loss in Q3 2023.
• For the nine months ended September 30, 2024, revenue increased by 7% to $11.3 million, compared to $10.6 million in the same period of 2023.
• The company's net loss for the nine months ended September 30, 2024 was $8.3 million, an improvement from the $9.3 million loss in the same period of 2023.
• Vivos has shifted its strategy to focus on strategic alliances with sleep centers, which is expected to drive future revenue growth.
• The company closed a $7.5 million equity private placement in June 2024, which has bolstered its cash position and facilitated the new strategic alliance.

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth and cost management, but the company is still operating at a loss and is reliant on additional financing. The strategic shift towards alliances is promising, but its success remains to be seen. The sentiment is cautiously optimistic.

Positives

• The company experienced a significant increase in product revenue, particularly in appliance sales.
• Gross profit margin improved, indicating better cost management and pricing strategies.
• Operating expenses decreased, reflecting cost-cutting measures and improved efficiency.
• The company's net loss improved, suggesting progress towards profitability.
• The strategic shift towards alliances with sleep centers is expected to drive future revenue growth.
• The $7.5 million equity private placement has strengthened the company's financial position.
• The company has seen a higher incidence of breakage in contracts, which accelerated revenue recognition.
• The company has seen a 17% increase in revenue for the nine months ended September 30, 2024.

Negatives

• VIP enrollment revenue decreased, indicating a need to refine the enrollment strategy.
• The company continues to operate at a net loss, highlighting the need for further improvements in profitability.
• The company's cash and cash equivalents may not be sufficient to fund operations and strategic objectives over the next twelve months.
• The company is still reliant on additional financing to sustain operations until it can achieve profitability and positive cash flows.

Risks

• The company's new strategic alliance model is unproven and may not increase revenues as anticipated.
• The company's cash and cash equivalents may not be sufficient to fund operations and strategic objectives over the next twelve months.
• The company is reliant on additional financing to sustain operations until it can achieve profitability and positive cash flows.
• There is a risk that the company will be unable to raise sufficient capital or generate sufficient revenue to maintain compliance with Nasdaq listing requirements.
• The company is subject to risks related to inflation, supply chain disruptions, and global economic uncertainty.
• The company is involved in ongoing litigation, which could have an adverse impact on its business.

Future Outlook

The company is focused on expanding its strategic alliances with sleep centers and other healthcare providers to drive revenue growth. Management is reviewing all options to obtain additional financing to fund operations and is working towards achieving profitability and positive cash flows.

Management Comments

• The company is placing significant emphasis on its new provider-based marketing and distribution model to grow revenues.
• The company believes that the new strategic alliance model will provide an important opportunity to increase revenues going forward.
• Management is reviewing all options to obtain additional financing to fund operations.

Industry Context

The company's strategic shift towards alliances with sleep centers reflects a broader trend in the healthcare industry towards integrated care models. The company's focus on non-surgical treatments for sleep apnea aligns with a growing patient preference for less invasive options. The company's efforts to expand its distribution network through partnerships with companies like Lincare and NOUM DMCC are consistent with industry trends towards broader market access.

Comparison to Industry Standards

• Vivos' revenue growth of 17% in Q3 2024 is a positive sign, but it is important to compare this to the growth rates of other medical device companies in the sleep apnea space. Companies like ResMed and Philips, which are larger and more established, typically have more stable growth rates, but Vivos' growth rate is higher than many smaller companies.
• The gross margin of 60% in Q3 2024 is competitive with other medical device companies, but it is important to monitor this metric to ensure that it remains sustainable as the company scales its operations.
• The company's net loss of $2.6 million in Q3 2024 is a concern, but it is important to note that many early-stage medical device companies operate at a loss while they are investing in research and development and building their sales infrastructure. The company's ability to reduce its net loss over time will be a key factor in its long-term success.
• The company's strategic shift towards alliances with sleep centers is a novel approach that could give it a competitive advantage over other companies that rely more heavily on direct sales to dentists. However, it is important to monitor the success of this strategy to ensure that it is generating the desired results.
• The company's reliance on third-party manufacturers is common in the medical device industry, but it is important to ensure that these manufacturers are able to meet the company's quality standards and production timelines.

Legal Proceedings

• The company is involved in ongoing litigation with Ortho-Tain, Inc. in two separate cases.
• The company is seeking relief from certain false, threatening, and defamatory statements to its business affiliate, Benco Dental.
• Ortho-Tain alleges violation of the Lanham Act and an alleged civil conspiracy among the defendants to violate the Lanham Act.

Stakeholder Impact

• Shareholders may benefit from the company's revenue growth and strategic shift, but they are also exposed to the risks associated with the company's ongoing losses and reliance on additional financing.
• Employees may be affected by the company's cost-cutting measures and strategic changes.
• Customers (dentists and patients) may benefit from the company's expanded product offerings and treatment options.
• Suppliers may be affected by the company's supply chain management and sourcing strategies.
• Creditors may be exposed to the risks associated with the company's ongoing losses and reliance on additional financing.

Next Steps

• The company will focus on expanding its strategic alliances with sleep centers.
• The company will continue to refine its marketing and distribution model.
• The company will work towards achieving profitability and positive cash flows.
• The company will continue to monitor and address any potential supply chain issues.
• The company will continue to monitor and address any potential legal issues.

Key Dates

Keywords

Vivos Therapeutics, sleep apnea, oral appliances, strategic alliance, revenue growth, financial results, medical devices, dental, VIP program, private placement